Myonex, a leading global clinical trial supply company has acquired the Clinical Trial and Wholesale Drug Business of Hubertus located in Berlin, Germany. Myonex and the owners of Hubertus also have entered a cooperation agreement with the remaining Pharmacy Business of Hubertus to support decentralized clinical trials (DCTs). The closing of the acquisition is expected to occur in the coming months after the completion of the appropriate regulatory licensing approvals.

“Myonex has enjoyed tremendous growth in recent years. These agreements expand Myonex’s Clinical Trial Packaging and Distribution capabilities in the European Union. They strengthen Myonex’s ability to support decentralized clinical trials, including direct to patient shipments. They will enable Myonex to increase direct sourcing options for our customers’ clinical trials in the post-Brexit environment,” said James Lovett, Chief Executive Officer at Myonex.

Myonex and Hubertus both originated as pharmacies more than 30 years ago, share similar cultures, with solid reputations for providing tailored solutions and reliable service and a strong emphasis on people and quality.

”I am happy that Myonex, a company sharing our values and being family-owned as well, will continue the great work we’ve started as Hubertus 30 years ago in the clinical trial and wholesale business. And I am looking forward to accompanying the future of Myonex in Germany as a strategic partner,” says Bernd Drevenstedt.